Financhill
Buy
54

ATRC Quote, Financials, Valuation and Earnings

Last price:
$38.47
Seasonality move :
-4.34%
Day range:
$37.22 - $39.12
52-week range:
$18.94 - $39.12
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
4.02x
P/B ratio:
4.03x
Volume:
903.1K
Avg. volume:
476.3K
1-year change:
15.15%
Market cap:
$1.9B
Revenue:
$399.2M
EPS (TTM):
-$0.83

Analysts' Opinion

  • Consensus Rating
    AtriCure has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $45.11, AtriCure has an estimated upside of 17.26% from its current price of $38.47.
  • Price Target Downside
    According to analysts, the lowest downside price target is $36.00 representing 100% downside risk from its current price of $38.47.

Fair Value

  • According to the consensus of 5 analysts, AtriCure has 17.26% upside to fair value with a price target of $45.11 per share.

ATRC vs. S&P 500

  • Over the past 5 trading days, AtriCure has overperformed the S&P 500 by 19.01% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • AtriCure does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • AtriCure has grown year-over-year revenues for 15 quarters straight. In the most recent quarter AtriCure reported revenues of $115.9M.

Earnings Growth

  • AtriCure has grown year-over-year earnings for 0 quarters straight. In the most recent quarter AtriCure reported earnings per share of -$0.17.
Enterprise value:
1.8B
EV / Invested capital:
--
Price / LTM sales:
4.02x
EV / EBIT:
--
EV / Revenue:
4.04x
PEG ratio (5yr expected):
-0.86x
EV / Free cash flow:
-1,565.92x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$334.7M
Return On Assets:
-6.45%
Net Income Margin (TTM):
-8.7%
Return On Equity:
-8.42%
Return On Invested Capital:
-7.42%
Operating Margin:
-6.39%
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue $315.6M $380.7M $447.6M $98.3M $115.9M
Gross Profit $235.8M $285.7M $334.7M $73.9M $86.8M
Operating Income -$51M -$22.2M -$34.2M -$8.1M -$7.4M
EBITDA -$39.7M -$4.2M -$12.9M -$3.1M -$936K
Diluted EPS -$1.22 -$0.54 -$0.83 -$0.20 -$0.17
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $296.2M $195.7M $212.3M $252.7M $269.3M
Total Assets $707.8M $613M $581.9M $600.3M $615.1M
Current Liabilities $44.8M $54M $57.6M $82.5M $74.4M
Total Liabilities $290.3M $124.5M $131.6M $137.4M $150M
Total Equity $417.5M $488.5M $450.3M $462.8M $465M
Total Debt $62.1M $60.9M $60.1M $62.9M $61.9M
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations -$21.9M $500K $10.4M $1.5M $20M
Cash From Investing $38.1M $31.6M $42.1M $11.9M $4.4M
Cash From Financing -$6.5M -$409K -$3M $132K -$333K
Free Cash Flow -$37.3M -$42.9M -$1.2M -$2.1M $16.4M
ATRC
Sector
Market Cap
$1.9B
$44.9M
Price % of 52-Week High
98.34%
46.55%
Dividend Yield
0%
0%
Shareholder Yield
0.51%
-0.75%
1-Year Price Total Return
15.15%
-33.54%
Beta (5-Year)
1.419
0.746
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $34.99
200-day SMA
Buy
Level $27.04
Bollinger Bands (100)
Buy
Level 27.34 - 34.94
Chaikin Money Flow
Buy
Level 29.3M
20-day SMA
Buy
Level $32.51
Relative Strength Index (RSI14)
Buy
Level 70.10
ADX Line
Buy
Level 32.25
Williams %R
Sell
Level -6.9742
50-day SMA
Buy
Level $34.17
MACD (12, 26)
Buy
Level 1.06
25-day Aroon Oscillator
Buy
Level 68
On Balance Volume
Neutral
Level 49.2M

Financial Scores

Buy
Altman Z-Score (Annual)
Level (6.975)
Buy
CA Score (Annual)
Level (0.8611)
Buy
Beneish M-Score (Annual)
Level (-2.5682)
Buy
Momentum Score
Level (5)
Buy
Ohlson Score
Level (-0.5364)
Buy
Piotroski F Score (Annual)
Level (6)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (5)

Revenue Forecast

Earnings per Share Forecast

Company Profile

AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation Pacing and Sensing, and others. The company also offers a variety of minimally invasive ablation devices and access tools to facilitate the growing trend in less invasive cardiac and thoracic surgery. Geographically, it generates a majority of its revenue from the United States.

Stock Forecast FAQ

In the current month, ATRC has received 5 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ATRC average analyst price target in the past 3 months is $45.11.

  • Where Will AtriCure Stock Be In 1 Year?

    According to analysts, the consensus estimate is that AtriCure share price will rise to $45.11 per share over the next 12 months.

  • What Do Analysts Say About AtriCure?

    Analysts are divided on their view about AtriCure share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that AtriCure is a Sell and believe this share price will drop from its current level to $36.00.

  • What Is AtriCure's Price Target?

    The price target for AtriCure over the next 1-year time period is forecast to be $45.11 according to 5 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.

  • Is ATRC A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for AtriCure is a Buy. 5 of 5 analysts rate the stock a Buy at this time.

  • How Can I Buy Shares Of ATRC?

    You can purchase shares of AtriCure via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase AtriCure shares.

  • What Is The AtriCure Share Price Today?

    AtriCure was last trading at $38.47 per share. This represents the most recent stock quote for AtriCure. Yesterday, AtriCure closed at $38.47 per share.

  • How To Buy AtriCure Stock Online?

    In order to purchase AtriCure stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Where Will TJX Companies Stock Be in 10 Years?
Where Will TJX Companies Stock Be in 10 Years?

Off-price retail is as popular as ever thanks to social…

Will CVS Health Stock Recover?
Will CVS Health Stock Recover?

It’s been a treacherous journey for CVS Health Corporation (NYSE:CVS)…

Why Is AT&T Stock Dropping?
Why Is AT&T Stock Dropping?

The telecommunications giant AT&T Inc. (NYSE:T) has perhaps surprisingly eclipsed…

Stock Ideas

Sell
46
Is AAPL Stock a Buy?

Market Cap: $3.5T
P/E Ratio: 38x

Buy
51
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 115x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Alerts

Sell
45
QMCO alert for Jan 16

Quantum [QMCO] is down 0% over the past day.

Buy
51
QRVO alert for Jan 16

Qorvo [QRVO] is down 0% over the past day.

Sell
31
ATEX alert for Jan 16

Anterix [ATEX] is down 0% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock